CANASA®
Wholesaler Order Entry Numbers
Canasa® 1000mg 30ct. NDC# 58914-501-56
| Wholesaler | Canasa® 1000mg 30 count box |
| AmerisourceBergen (6 digit) | 510887 |
| AmerisourceBergen (7 digit) | 4848313 |
| Bellco Drug Co. | 110867 |
| Burlington Drug | 603172 |
| Cardinal Health | 3640638 |
| Dakota Drug | 494179 |
| Dohmen (Southeast) | 156026 |
| D&K (Walsh, Diversified, Jewett, San Antonio) | 047155 |
| Dik Drug | 150896 |
| HD Smith | 1713387 |
| F. Dohmen Co. | 860882 |
| F.W. Kerr | 027-052 |
| King Drug | TBD |
| Kinray | 855783 |
| Mc Query Bros. | 145-920 |
| Miami Luken | 031-567 |
| Morris & Dickson | 617084 |
| Mc Kesson | 1207232 |
| Prescription Supply Inc. | 385104 |
| Quality King Dist. | 00414 |
| Rochester Drug Cooperative | 10099463 |
| Smith Drug | 07-2003 |
| The Harvard Drug Group | TBD |
| Valley Wholesaler | 212019 |
| Value Drug Co. | TBD |
First Databank GCN Code: 48490
Medispan GPI Code: 52500030005240
Information on this website is not intended to replace the advice of your physician(s). Please consider what you learn here a starting point for a conversation with your physician. All care of ulcerative proctitis and related conditions must be guided by the appropriate healthcare professional. CANASA® is a prescription drug.
CANASA® is available by prescription only.
CANASA® 1000 mg Suppositories are indicated for the treatment of active ulcerative proctitis.
CANASA® is contraindicated in patients who have demonstrated hypersensitivity to mesalamine (5-aminosalicylic acid) or to the suppository vehicle [saturated fatty acid esters (Hard Fat, NF)], or to salicylates (including Aspirin).
As with other mesalamine containing products, less common but possibly serious side effects such as acute intolerance syndrome, pericarditis and pancolitis may occur.
Patients on CANASA® 1000 mg, especially those on concurrent oral products which contain or release mesalamine and those with pre-existing renal disease, should be carefully monitored with urinalysis, BUN and creatinine testing.
Caution should be exercised when CANASA® suppositories are initially used in patients known to be allergic to sulfasalazine.
CANASA® was generally well tolerated in clinical studies. The most common side effects of CANASA® are dizziness (3%), rectal pain (1.8%), fever (1.2%), rash (1.2%), acne (1.2%), and colitis (1.2%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.FDA.gov/medwatch, or call 1-800-FDA-1088.
